Zhejiang Chimin Pharm Co Ltd (603222) - Total Liabilities
Based on the latest financial reports, Zhejiang Chimin Pharm Co Ltd (603222) has total liabilities worth CN¥1.07 Billion CNY (≈ $156.24 Million USD) as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Zhejiang Chimin Pharm Co Ltd - Total Liabilities Trend (2011–2025)
This chart illustrates how Zhejiang Chimin Pharm Co Ltd's total liabilities have evolved over time, based on quarterly financial data. See 603222 current assets to equity ratio to evaluate short-term liquidity relative to the company's equity base.
Zhejiang Chimin Pharm Co Ltd Competitors by Total Liabilities
The table below lists competitors of Zhejiang Chimin Pharm Co Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Neuropace Inc
NASDAQ:NPCE
|
USA | $84.44 Million |
|
ZF Commercial Vehicle Control Systems India Limited
NSE:ZFCVINDIA
|
India | Rs6.01 Billion |
|
Anhui Province Natural Gas Development Co Ltd
SHG:603689
|
China | CN¥3.61 Billion |
|
SANTANDER UK 8 5/8% NON-CUM STLG PRF
LSE:SANB
|
UK | GBX251.69 Billion |
|
Napatech A/S
OL:NAPA
|
Norway | Nkr59.29 Million |
|
Nanjing Baose Co Ltd
SHE:300402
|
China | CN¥1.03 Billion |
|
Esso S.A.F.
PA:ES
|
France | €2.75 Billion |
|
ZimVie Inc
NASDAQ:ZIMV
|
USA | $345.42 Million |
Liability Composition Analysis (2011–2025)
This chart breaks down Zhejiang Chimin Pharm Co Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see 603222 market cap overview.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.78 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.96 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.47 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Zhejiang Chimin Pharm Co Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Zhejiang Chimin Pharm Co Ltd (2011–2025)
The table below shows the annual total liabilities of Zhejiang Chimin Pharm Co Ltd from 2011 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | CN¥1.00 Billion ≈ $146.93 Million |
+18.66% |
| 2024-12-31 | CN¥846.22 Million ≈ $123.83 Million |
+3.18% |
| 2023-12-31 | CN¥820.13 Million ≈ $120.01 Million |
-12.72% |
| 2022-12-31 | CN¥939.64 Million ≈ $137.50 Million |
-10.55% |
| 2021-12-31 | CN¥1.05 Billion ≈ $153.72 Million |
-15.67% |
| 2020-12-31 | CN¥1.25 Billion ≈ $182.29 Million |
+23.13% |
| 2019-12-31 | CN¥1.01 Billion ≈ $148.04 Million |
-6.17% |
| 2018-12-31 | CN¥1.08 Billion ≈ $157.78 Million |
+66.75% |
| 2017-12-31 | CN¥646.63 Million ≈ $94.62 Million |
+469.79% |
| 2016-12-31 | CN¥113.49 Million ≈ $16.61 Million |
+22.00% |
| 2015-12-31 | CN¥93.02 Million ≈ $13.61 Million |
-50.65% |
| 2014-12-31 | CN¥188.49 Million ≈ $27.58 Million |
-16.32% |
| 2013-12-31 | CN¥225.24 Million ≈ $32.96 Million |
-12.73% |
| 2012-12-31 | CN¥258.10 Million ≈ $37.77 Million |
-5.20% |
| 2011-12-31 | CN¥272.26 Million ≈ $39.84 Million |
-- |
About Zhejiang Chimin Pharm Co Ltd
Chimin Health Management Co., Ltd., together with its subsidiaries, researches, develops, produces, and sells vitro diagnostic products and provides medical services in China and internationally. The company provides non-PVC double-tube double-valve, single-tube single-valve, and single-tube double-valve soft bags; plastic bottles; and other packaging forms. It also offers medical instruments, in… Read more